Clin Exp Reprod Med.
2013 Jun;40(2):83-89. 10.5653/cerm.2013.40.2.83.
Cessation of gonadotropin-releasing hormone antagonist on triggering day in flexible multiple-dose protocol: A randomized controlled study
- Affiliations
-
- 1Health Promotion Center, Seoul National University Bundang Hospital, Seongnam, Korea.
- 2Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea. suhcs@snubh.org
- 3Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
- 4Maria Infertility Hospital, Seoul, Korea.
- KMID: 1493214
- DOI: http://doi.org/10.5653/cerm.2013.40.2.83
Abstract
OBJECTIVE
To investigate outcomes of stimulated IVF cycles in which GnRH antagonist was omitted on the ovulation triggering day.
METHODS
A total of 86 women who underwent controlled ovarian hyperstimulation with recombinant FSH and GnRH antagonist flexible multiple-dose protocols were recruited and prospectively randomized into the conventional group (group A) or cessation group (group B). The GnRH antagonist, 0.25 mg/day of cetrorelix, was started when the leading follicle reached 14 mm in diameter and was continuously administered until the hCG triggering day (group A, 43 cycles) or until the day before hCG administration (group B, 43 cycles). The maturity of oocytes, fertilization rate, embryo quality, and implantation and clinical pregnancy rates were evaluated.
RESULTS
The duration of ovarian stimulation, total dose of gonadotropins, serum estradiol levels on hCG administration day, and number of oocytes retrieved were not significantly different between the two groups. The total dose of GnRH antagonist was significantly lower in group B than group A (2.5+/-0.9 vs. 3.2+/-0.8 ampoules, p<0.05). There was no premature luteinization in any of the subjects. The proportion of mature oocytes and fertilization rate were not significantly different in group B than group A (70.7% vs. 66.7%; 71.1% vs. 66.4%, respectively). There were no significant differences in the implantation or clinical pregnancy rates.
CONCLUSION
Our prospective randomized study suggested that cessation of GnRH antagonist on the hCG administration day during a flexible multiple-dose protocol could reduce the total dose of GnRH antagonist without compromising its effects on pregnancy rates.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Cessation of Gonadotropin-Releasing Hormone Antagonist on Triggering Day: An Alternative Method for Flexible Multiple-Dose Protocol
- A Study of Clinical Efficacy of GnRH Antagonist (Cetrorelix) Single and Multiple Dose Protocol for Controlled Ovarian Hyperstimulation
- Clinical efficacy of GnRH antagonist multiple dose protocol and GnRH agonist long protocol in controlled ovarian hyperstimulation using rFSH in IVF-ET patients
- Effectiveness of Soft Stimulation Protocol, Compared with Conventional GnRH Antagonist Multiple dose Protocol in Patients Undergoing Controlled Ovarian Stimulation with Intrauterine Insemination
- The effective of ultrashort-term gonadotropin-releasing hormone agonist administration in controlled ovarian hyperstimulation for in vitro fertilization
